143 related articles for article (PubMed ID: 38728380)
1. Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Scheid C; Eikema DJ; Van Gelder M; Salmenniemi U; Maertens J; Passweg JR; Blaise D; Byrne JL; Kroeger N; Sockel K; Chevallier P; Bourhis JH; Cornelissen JJ; Sengeloev H; Finke J; Snowden JA; Gedde-Dahl T; Cornillon J; Schanz U; Patel A; Koster L; de Wreede LC; Hayden PJ; Raj K; Drozd-Sokolowska J; Gurnari C; Onida F; McLornan DP; Robin M; Yakoub-Agha I
Blood; 2024 May; ():. PubMed ID: 38728380
[TBL] [Abstract][Full Text] [Related]
2. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
3. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.
Reis-Alves SC; Traina F; Harada G; Campos PM; Saad ST; Metze K; Lorand-Metze I
PLoS One; 2013; 8(12):e81048. PubMed ID: 24324660
[TBL] [Abstract][Full Text] [Related]
8. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
10. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
[No Abstract] [Full Text] [Related]
11. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
[TBL] [Abstract][Full Text] [Related]
12. Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?".
Arslan S; Nakamura R
Curr Hematol Malig Rep; 2020 Aug; 15(4):305-315. PubMed ID: 32222884
[TBL] [Abstract][Full Text] [Related]
13. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
Kim Y; Kim IH; Kim HJ; Park S; Lee KH; Kim SJ; Lee JH; Kim DY; Yoon SS; Kim YK; Jang JH; Park SY; Ahn JS; Cheong CW; Lee JH; Cheong JW;
Int J Hematol; 2014; 99(5):635-43. PubMed ID: 24648120
[TBL] [Abstract][Full Text] [Related]
14. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract][Full Text] [Related]
19. BMT for Myelodysplastic Syndrome: When and Where and How.
Jain AG; Elmariah H
Front Oncol; 2021; 11():771614. PubMed ID: 35070975
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome.
Suh KJ; Cheong JW; Kim I; Kim HJ; Shin DY; Koh Y; Yoon SS; Min YH; Ahn JS; Kim YK; Lee YG; Lee JO; Bang SM; Mun YC; Seong CM; Park Y; Kim BS; Hong J; Park J; Lee JH; Kim SY; Lee HG
PLoS One; 2016; 11(11):e0166245. PubMed ID: 27824923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
